Health ❯ Healthcare ❯ Medicine

Oncology

Chronic Lymphocytic Leukemia Breast Cancer Clinical Trials Glioblastoma Lung Cancer Multiple Myeloma Acute Myeloid Leukemia Prostate Cancer Lymphoma Chemotherapy Leukemia Biomarkers Personalized Medicine Mastocytosis Targeted Therapy Pancreatic Cancer Gastroesophageal Cancer Hepatocellular Carcinoma Neuro-oncology Meningioma Research Findings Radiation Therapy Hematology Cancer Biology Drug Combinations Non-Small Cell Lung Cancer Cancer Treatment Progression-Free Survival Immunotherapy

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

The result challenges the belief that RAS‑driven pancreatic tumors cannot be targeted.

Metformin Triggers Exercise-Linked Signal in Prostate Cancer Patients

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

Oncolytic Viruses Trigger T‑Cell Infiltration and Survival Signals in Early Glioblastoma Trials

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer